Original fundamental research starts and ENDS here.
Sectors Tags Blog
GILD
2 filings
Timeline Columns Start Research 8-K Categories
Showing: M&A Clear filter
2024
Q1 2 filings
Mar
Acquired CymaBay Therapeutics
$4.3B deal at $32.50 per share
8-K
Feb
Acquired CymaBay Therapeutics
$32.50 per share, $151.6M termination fee
8-K
SECENDS is not affiliated with the SEC. Data from public EDGAR filings. Not financial advice.